[Clinical trial od Di-n-propylacetate in epileptics with therapy-resistant absences].
The clinical trials of Di-n-propylacetate (Depakine, Labaz) produced favorable results with 15 patients, whose epilepsies were characterized by exceptional therapy-resistant absences, partly in combination with grand mal (4 patients). After discontinuation of DPA and renewed application of this drug at a later stage the patients made a good recovery.
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004832:Epilepsy, Absence / Q000188:drug therapy*; D004830:Epilepsy, Tonic-Clonic / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D014631:Valerates / Q000627:therapeutic use*
D000927:Anticonvulsants; D014631:Valerates
Klinische Prüfung von Di-n-propylazetat bei Epilepsien mit therapieresistenten Absencen